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InﬂammationWe previously reported the expression of angiopoietin receptor Tie2 on human neutrophils. Both angiopoie-
tins (Ang1 and Ang2) induce platelet activating factor (PAF) synthesis from endothelial cells (ECs) and neu-
trophils. Both angiopoietins can also modulate EC viability and since PAF can promote pro-survival activity on
neutrophils, we addressed whether Ang1 and/or Ang2 could modulate neutrophil viability. Neutrophils were
isolated from venous blood of healthy volunteers and neutrophil viability was assessed by ﬂow cytometry
using apoptotic and necrotic markers (annexin-V and propidium iodide (P.I.), respectively). Basal neutrophil
viability from 0 to 24 h post-isolation decreased from 98% to≈45%. Treatment with anti-apoptotic mediators
such as interleukin-8 (IL-8; 25 nM) and PAF (100 nM) increased neutrophil basal viability by 34 and 26%
(raising it from 43 to 58 and 55%) respectively. Treatment with Ang1 (0.001–50 nM) increased neutrophil vi-
ability by up to 41%, while Ang2 had no signiﬁcant effect. Combination of IL-8 (25 nM) or PAF (100 nM) with
Ang1 (10 nM) further increased neutrophil viability by 56 and 60% respectively. We also observed that Ang1,
but not Ang2 can promote IL-8 release and that a pretreatment of the neutrophils with blocking anti-IL-8 an-
tibodies inhibited the anti-apoptotic effect of IL-8 and Ang1 by 92 and 81% respectively. Pretreatment with a
selective PAF receptor antagonist (BN 52021), did abrogate PAF pro-survival activity, without affecting Ang1-
induced neutrophil viability. Our data are the ﬁrst ones to report Ang1 pro-survival activity on neutrophils,
which is mainly driven through IL-8 release.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Angiopoietins (Ang1 and Ang2) are growth factors structurally re-
lated, and contributing to angiogenesis upon binding to Tie2 receptor
[1]. Ang1 is known as a Tie2 agonist capable of inducing EC migration
and proliferation [2–5]. In addition, Ang1 promotes pericyte recruit-
ment to the newly formed vessels, therefore leading to the maturation
and stabilization of the vasculature [6,7]. Furthermore, Ang1 has the ca-
pacity to reduce apoptosis ofmany cellular types such as EC, cardiomyo-
cytes and mesenchymal stem cells [8–11]. This activity can lead to a
protective role of Ang1 in acute inﬂammatory conditions such as in
lung injury, and in chronic diseases such as cardiac remodeling where
Ang1 improves cardiomyocytes survival and reduces cardiac hypertro-
phy [12,13]. In contrast, Ang2was initially reported as a Tie2 antagonist,
inducing vascular permeability and EC apoptosis, therefore, leading to
the promotion of a pro-inﬂammatory environment and the destabiliza-
tion of pre-existing vasculature [14,15]. However, mounting evidencel Heart Institute, 5000 Belanger
6 3330x3583; fax: +1 514 376
ois).
l rights reserved.demonstrates that Ang2 could also have agonistic properties by being
able to induce Tie2 phosphorylation, EC chemotaxis and in vitro tubule
capillary-like formation [16–19]. In previous studies, we reported that
both angiopoietins exert pro-inﬂammatory activities on ECs by their ca-
pacity to stimulate PAF synthesis and P-selectin translocation, therefore
leading to neutrophil adhesion onto activated ECs and transmigration
[20–22]. Furthermore, angiopoietins can also modulate cytokine activi-
ties in ECs, for instance, at low concentrations, Ang2 is a priming factor
for tumor necrosis factor-α (TNF-α) [23] and both Ang1 and Ang2 have
been reported to potentiate VEGF-induced angiogenesis in amouse cor-
nea model [1].
We also reported the expression of Tie2 receptor on human neutro-
phils, and that both angiopoietins can promote pro-inﬂammatory activ-
ities on neutrophils [22]. Ang1 and Ang2 support neutrophil PAF
synthesis, activation of CD11b/CD18 (β2-integrin), adhesion andmigra-
tion [22,24]. In addition, angiopoietins can also enhance the activities of
pro-inﬂammatory mediators, for instance, pretreatment with Ang1
and/or Ang2 potentiates IL-8-induced neutrophil migration [24].
Neutrophil lifespan is relatively short, ranging from 8 to 20 h in
blood circulation and up to few days in perivascular tissues [25–27].
Neutrophils are the primary leukocytes being recruited at inﬂammatory
sites and promote a range of pro-inﬂammatory activities, namely by
359E. Dumas et al. / Biochimica et Biophysica Acta 1823 (2012) 358–367their capacity to release various chemokines and cytokines, including
VEGF, TNF-α, IL-1, IL-8 and PAF [28,29]. Neutrophils can also secrete
catalytic enzymes (metalloproteinases, lysosymes), which contribute
to extracellular matrix degradation and elimination of pathogens
[29,30]. Increasing neutrophil viability can prolong and enhance the in-
ﬂammatory response, thus, contributing to the development and
progression of multiple vascular-associated diseases such as systemic
inﬂammatory response syndrome (SIRS), tumor growth, ischemia/
reperfusion injury and rheumatoid arthritis (RA) [26,31–35].
For instance, it has been reported that the expression of both angio-
poietins and members of Tie-receptor family (Tie1 and Tie2) is in-
creased in patients suffering from RA, and that the corresponding
expression is not limited to vascular cells, but also overexpressed in
stromal cells and in the synovial lining [36]. Such overexpression
could lead to the development of pathological angiogenesis, which
can be inhibited by the blockade of Ang/Tie ligand–receptor system
[37]. In addition, since RA is characterized as a chronic inﬂammatory
disease, angiopoietins could contribute to the inﬂammatory process
through their capacity to promote neutrophil-mediated pro-
inﬂammatory responses, namely through PAF and IL-8 participation
[22,24,38,39].
PAF is a bioactive lipid that derivates from arachidonic acid metabo-
lism acting through the stimulation of a G-protein-coupled receptor
(PAFR). This potent pro-inﬂammatory mediator is involved in inﬂam-
mation, reproduction, angiogenesis and tumor growth metastasis [40].
PAF activates and is produced by many inﬂammatory cells including
ECs, platelets, monocytes, lymphocytes and neutrophils. In addition, in
function of the cell type, PAF promotes many pro-inﬂammatory activi-
ties such as platelet aggregation and modulation of cell viability [41].
For instance, PAF promotes apoptosis on hepatocytes and neurons,
whereas it can prolong cell viability of various leukocytes, including
neutrophils [40,42].
IL-8 was ﬁrst described as a monocyte-derived neutrophil chemo-
tactic factor (MDNCF) [43–45], and subsequently reported for being
synthesized by ECs, ﬁbroblasts and keratinocytes [46,47]. IL-8 is a
major pro-inﬂammatory mediator, acting predominantly on neutro-
phils where it induces respiratory burst [48], generation of superoxide
and hydrogen peroxide [49], cellular reorganization [49], secretion of
catalytic enzymes (metalloproteinases, lysosymes) [50], synthesis of
bioactive lipids [51], translocation and activation of adhesionmolecules
[52], chemotaxis [53] and pro-survival activity [54]. IL-8 is also involved
in the development of various pathological conditions, such as acute re-
spiratory distress syndrome (ARDS), ischemia/reperfusion injury,
tumor growth and metastasis [46,54].
Since both angiopoietins can modulate endothelial cell survival
[10,11,17,55–57] and induce PAF synthesis [21,22] which supports
neutrophil viability [42], and that both angiopoietins can modulate
IL-8 chemotactic activity on neutrophils [24], we thus wanted to as-
sess whether Ang1 and/or Ang2 can modulate neutrophil viability,
and if so, delineate the potential contribution of speciﬁc cytokines
being synthesized and released by the neutrophils.
2. Material and methods
2.1. Neutrophil isolation and puriﬁcation
Human venous blood was obtained from consent healthy donors
free from medication for at least 10 days prior to the experiments and
in accordance with the guidelines of the Montreal Heart Institute's eth-
ical committee. Neutrophils were isolated as described previously
[22,24,58]. Neutrophils were then resuspended in RPMI medium
(Lonza, Basel, Switzerland) supplemented with 25 mM Hepes (N-2-
hydroxyethylpiperazine-N′-2-ethanesulfonic acid) and 1% penicillin/
streptomycin. At least 95% of isolated cells were neutrophils as deter-
mined by staining with Kwik Diff solutions according to the manufac-
turer's instructions (Thermo Fisher Scientiﬁc, Kalamazoo, MI, USA)and viability was found to be greater than 98% as assessed by Trypan
blue dye exclusion assay [59].
2.2. Assessment of viability, apoptosis and necrosis
Neutrophils were incubated in 24-well plates (Becton Dickinson,
San Jose, CA, USA) at 5×106 cells/well for different periods of time
(0–24 h) at 37 °C and treated with various agonists: Ang1 and Ang2
(R&D Systems, Minneapolis, MN, USA), IL-8 (Peprotech, Rocky Hill,
NJ, USA) and methylcarbamyl-PAF C-16 (PAF; Cayman Chemical,
Ann Arbor, MI, USA) in RPMI medium supplemented with 10%
human serum (Millipore, Billerica, MA, USA). In some experiments,
neutrophils were preincubated with a secreted phospholipase A2
(sPLA2) inhibitor, 12-epi-scalaradial (Biomol, Plymouth Meeting, PA,
USA), a cytosolic PLA2 (cPLA2) inhibitor, AACOCF3 (Cayman Chemi-
cal), a PAF receptor antagonist, BN 52021 (Sigma-Aldrich, St. Louis,
MO, USA), a goat polyclonal blocking anti-human Tie2 antibody
(R&D Systems, #AF313), a goat polyclonal blocking anti-human IL-
8 antibody (R&D Systems, #AB-208-NA) or control IgG isotype for
30 min to 2 h prior to the addition of selected agonists. Viability was
measured by ﬂow cytometry using annexin-V-ﬂuorescein isothiocya-
nate (FITC) and P.I. (Becton Dickinson) as previously described
[60,61]. Brieﬂy, neutrophils (1×106 cells/50 μl) were rinsed with
PBS, centrifuged (900 g, 7 min at 4 °C), resuspended in annexin-V
binding buffer (10 mM Hepes, 140 mM NaCl, 2.5 mM CaCl2, pH 7.4)
(Becton Dickinson) and incubated in the dark for 15 min at room
temperature in the presence of 2.5 μl of annexin-V-FITC (20 μg/ml in
aqueous buffered solution containing BSA and 0.09% sodium azide)
and 5 μl of P.I. (50 μg/ml in PBS, pH 7.4) (PharMingen, Becton Dickin-
son). Flow cytometry analyses (15000 events per tube) were per-
formed using a ﬂow cytometer with a 488 nm wavelength argon
laser (Coulter EPICS XL, Beckman Coulter, Brea, CA, USA). Intact neu-
trophils were selected according to size and granularity. Cells nega-
tive for both annexin-V and P.I. were considered as viable (annexin-
V−/P.I.−), annexin-V-positive and P.I.-negative cells were considered
as early apoptotic (annexin-V+/P.I.−) and cells positive for both
markers were considered as necrotic and/or in late apoptotic phase
(annexin-V+/P.I.+).
2.3. Morphological assessment of neutrophil apoptosis
Viability was also assessed by morphological observations as pre-
viously described [27]. Neutrophils (5×105 cells/condition) were
cytocentrifuged, ﬁxed and stained for 30 s with hematoxylin QS (Vec-
tor Laboratories, Burlingame, CA, USA). Neutrophils were examined
under oil immersion light microscopy at 400× magniﬁcation. Cells
in ﬁve random ﬁelds per condition were analyzed and apoptotic/ne-
crotic cells were characterized by condensed and darkly stained nu-
clei. At least 400 neutrophils were counted per condition. Flow
cytometry and morphological assessment gave similar results in re-
gard to neutrophil viability.
2.4. Neutrophil chemotactic activity
In vitro chemotactic assays were performed in Transwell-96 well
permeable supports. The top and the bottom well were separated
by a porous polycarbonate membrane ﬁlter (3 μm pore size) (Corning
Life Science, Corning, NY) as previously described [62,63]. Brieﬂy, the
bottom wells were loaded with RPMI containing PBS, IL-8 (25 nM) or
fMLP (0.1–10 μM) to a ﬁnal volume of 230 μl. The top wells were
loaded with neutrophils (107 cells/ml; 80 μl from a RPMI suspension).
In function of the experiments, neutrophils were freshly added post-
isolation or pretreated for 24 h with PBS or Ang1 (10 nM) prior to the
chemotactic assay. The Transwell-96 well permeable supports were
incubated at 37 °C for 1 h in a humidiﬁed incubator in the presence
of 5% CO2. At the end of the incubation period, the supernatant from
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Fig. 1. Effect of angiopoietins on neutrophil viability in a concentration-dependent man-
ner. Human neutrophils were incubated with PAF (100 nM; positive control), Ang1
(0.001–50 nM) (A) and Ang2 (0.001–50 nM) (B) for 24 h at 37 °C. Neutrophils were con-
sidered viable in the absence of positive staining for both markers (annexin-V and P.I.;
annexin-V−/P.I.−). Neutrophils were considered under apoptotic state when they stained
positively for annexin-V and negatively for P.I. (annexin-V+/P.I.−). Neutrophils were con-
sidered necrotic when they stained positively for both markers (annexin-V+/P.I.+).
*pb0.05; **pb0.01 and ***pb0.001 as compared to PBS-treated cells.
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was assessed with an Amnis ImageStream system.
2.5. Statistical analysis
Results from each experiment are the mean of cumulative inde-
pendent experiments from the blood of at least three independent
donors, and expressed as the mean±SEM. Comparisons were made
by analysis of variance (ANOVA) followed by a Dunnett's test. Differ-
ences were considered signiﬁcant at p values≤0.05.
3. Results
3.1. Ang1, but not Ang2, promotes neutrophil viability
It has been reported that Ang1 and Ang2modulate EC survival while
PAF increases neutrophil viability [10,11,17,42,56,57,64]. On our side,
we have reported that both angiopoietins induce PAF synthesis in neu-
trophils [22]. Thus, we sought to determine whether angiopoietins
could modulate neutrophil viability and the potential role of PAF. In a
ﬁrst series of experiments we assessed the survival rate of neutrophils
on a 24-hour period. Upon neutrophil isolation, the viability of the
cells was ≈98% and declined time-dependently to ≈45% after 24 h.
We then used PAF as a positive control to promote neutrophil viability.
Upon a 24-hour incubation period, we observed a bell-shape
concentration-dependent anti-apoptotic effect of PAF (1–10000 nM)
on neutrophil viability with an optimal effect being achieved at
100 nM, providing a 26% increase of neutrophil viability (raising the
basal viability from 43.4 to 54.8%) (Suppl. data Fig. 1).
We then assessed the capacity of both angiopoietins (Ang1 and
Ang2) to modulate neutrophil viability on a concentration- and time-
dependent manner. Treatment with Ang1 (0.001–50 nM;
0.07–3500 ng/ml) increased signiﬁcantly neutrophil viability at 1, 10
and 50 nM, raising the basal viability from 43.4 to 53.3, 59.0 and 61.3%
respectively (corresponding to a 23, 36 and 41% increase). Interestingly,
in the current set of experiments, Ang1 at 10 nMwas already more po-
tent than PAF (100 nM) to promote neutrophil viability (Fig. 1A). To as-
sess whether Ang1-mediated pro-survival activity was caused by an
effect on apoptosis or necrosis, we evaluated the effect of Ang1 on neu-
trophil viability with two speciﬁc markers of membrane asymmetry,
annexin-V-FITC (phosphatidylserine externalization; apoptosis) and
P.I. (intercalating agent; necrosis). These data were further conﬁrmed
by cytologic staining and morphological assessment of neutrophil via-
bility under optical microscopy. The beneﬁcial effect of Ang1 on neutro-
phil viability is observed by its capacity to reduce the apoptotic and
necrotic events. In fact, PAF and Ang1 had a similar capacity to signiﬁ-
cantly lower neutrophil apoptosis (reducing it from 38.9% to 34.1%
and 29.4% respectively). In addition, PAF and Ang1 had a similar capac-
ity to signiﬁcantly lower neutrophil necrosis (reducing it from 15.9% to
8.8% and 9.7% respectively) (Fig. 1A). In parallel,we performed the same
experiments with neutrophils from the same donors and observed that
Ang2 (0.001–50 nM; 0.066–3300 ng/ml) as opposed to Ang1, had no
signiﬁcant effect on neutrophil viability (Fig. 1B). As the maximal effect
mediated by Ang1was nearly achieved at 10 nM,we elected to limit the
use of Ang1 up to 10 nM for upcoming experiments.
We then treated the neutrophils with the angiopoietins (Ang1,
Ang2; 1 and 10 nM) and PAF (100 nM; positive control) on a 24-hour
time period to address the kinetic of Ang1-mediated anti-apoptotic ac-
tivity. Treatment with Ang1 (1 and 10 nM; 70 and 700 ng/ml) provided
a positive trend onneutrophil viability upon 12 h post-isolation, and the
Ang1 anti-apoptotic effect was signiﬁcant andmaximal (10 nM) at 24 h
(Fig. 2A). By performing a time-response kinetic, we were led to ob-
serve that Ang1 (1 and 10 nM) had a beneﬁcial pro-survival activity
by delaying the entry of neutrophils into apoptotic and necrotic phases
(Fig. 2B–C). Treatment with PAF (100 nM) or Ang1 (1 and 10 nM) at
24 h signiﬁcantly reduced neutrophil apoptosis by 12, 13 and 24%respectively. In addition, treatment with PAF (100 nM) or Ang1 (1
and 10 nM) at 24 h also signiﬁcantly decreased neutrophil necrosis by
45, 31 and 39% respectively (Fig. 2C). Since pro-survival activity of
Ang1 and PAF on neutrophils was optimal at 24 h, our experiments
were subsequently performed at 24 h post-isolation. The same experi-
ments were performed in parallel with Ang2 (1 and 10 nM; 66 and
660 ng/ml). Again, we observed that Ang2 had no effect on neutrophil
viability, apoptosis and necrosis from 0 to 24 h post-isolation (Fig. 2A–
C).
3.2. Ang1-mediated pro-survival activity is Tie2-dependent
In previous studies, we and other groups observed that angiopoie-
tins could mediate their biological activities upon binding and activa-
tion of Tie2 receptor [22,24,65,66]. Thus, we wanted to assess if the
pro-survival activity of Ang1 is implying Tie2 participation. In the cur-
rent set of experiments, neutrophils were pretreated with a goat poly-
clonal blocking anti-human Tie2 antibody (5, 10 or 20 μg/ml) or
control goat IgG isotype (20 μg/ml) for 1 h before stimulation with
PBS or Ang1 (10 nM) for an additional 23 h. Treatment with control
goat IgG orwith anti-Tie2 blocking antibodies (20 μg/ml) had no signif-
icant effect on basal neutrophil viability (Fig. 3). Pretreatment of
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Fig. 2. Effect of Ang1 and Ang2 on neutrophil viability in a time-dependent manner.
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(100 nM) from 0 to 24 h at 37 °C. (A) Viable neutrophils, (B) apoptotic neutrophils
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concentration-dependent manner the pro-survival activity of Ang1
with a maximal effect being achieved at 20 μg/ml (84% inhibition)
(Fig. 3). Pretreatment of neutrophils with anti-Tie2 blocking antibodies
did not reverse Ang1 mediated anti-apoptotic activity but did abrogate
Ang1-anti-necrotic activity (Fig. 3).3.3. Additive effect of PAF and Ang1 on neutrophil viability
Since PAF is a neutrophil pro-survival mediator [42], and as ob-
served in our current study, we thus wanted to address whether
both angiopoietins and PAF could cooperate on neutrophil viability.
Neutrophils were treated with Ang1 (0.1–10 nM) in the presence or
absence of PAF (100 nM) for 24 h. Treatment with PAF or Ang1 (1
and 10 nM) increased neutrophil viability by 26, 23 and 36% respec-
tively (Fig. 4). Combining PAF (100 nM) with Ang1 (1 and 10 nM)
provided an additive effect, increasing by 48 and 60% the viability of
the neutrophils (raising the basal neutrophil viability from 43.4 to
64.4 and 69.6%, respectively). Furthermore, the combination of PAF
(100 nM) with Ang1 (1 and 10 nM) provided a signiﬁcant increase
of neutrophil survival as compared to the cells treated either with
PAF (100 nM) or Ang1 (1 or 10 nM) alone (Fig. 4). Neutrophils were
also treated with Ang1 (0.1 nM) to assess whether PAF (100 nM)
could prime an effect of Ang1 at a concentration, which by itself
does not induce neutrophil viability. This latter combination did not
provide an additive effect on neutrophil viability (Fig. 4). In addition,
treatment of neutrophils with PAF or Ang1 provided a signiﬁcant
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10 nM) provided an additive capacity to decrease neutrophil apopto-
sis as compared to the cells treated either with PAF (100 nM) or Ang1
(10 nM) alone (Fig. 4). Finally, the combination of PAF (100 nM) with
Ang1 (1 and 10 nM) provided a signiﬁcant decrease of neutrophil ne-
crosis as compared to the cells treated either with PAF (100 nM) or
Ang1 (1 or 10 nM) alone (Fig. 4).
3.4. Contribution of PAF on Ang1 pro-survival activity
In the current setting of experiments, we wanted to address if en-
dogenous PAF is involved in Ang1 pro-survival activity on neutro-
phils. We thus pretreated neutrophils with a selective PAF receptor
antagonist (BN 52021; 50 and 100 μM) [67,68], or the corresponding
control vehicle (DMSO) for 1 h prior to the addition of PAF (100 nM)
or Ang1 (10 nM) for an additional 23 h. Treatment with BN 52021
alone did not modulate basal neutrophil viability. In pretreatment,
BN 52021 abrogated completely PAF-mediated pro-survival activity,
bringing the survival rate of the neutrophil even below to the
control-PBS level (Fig. 5). In addition, a pretreatment with BN
52021 abrogated as well the PAF-mediated anti-apoptotic effect on
neutrophils (Fig. 5). On the other hand, a pretreatment with BN
52021 did not modulate signiﬁcantly the effect of Ang1 on neutrophil
viability, apoptosis and necrosis (Fig. 5). We previously reported that
in ECs, both angiopoietins induce PAF synthesis through the activa-
tion of sPLA2-V and independently from cPLA2 activation [21]. In
function of the stimulus, both PLA2s can be activated to promote neu-
trophil PAF synthesis [69–73]. We thus pretreated the neutrophils
with a sPLA2 inhibitor (scalaradial; up to 20 μM) [21,74,75], a cPLA2
inhibitor (AACOCF3; up to 20 μM) [21,74–76] or their corresponding
control vehicles (DMSO or ethanol, respectively) for 1 h prior to the
addition of Ang1 (10 nM) for an additional 23 h. Treatment with
both inhibitors (AACOCF3 and scalaradial) did not modulate Ang1
pro-survival activity on neutrophils (data not shown).
3.5. Additive effect of IL-8 and Ang1 on neutrophil viability
We reported that both angiopoietins can potentiate IL-8-induced
neutrophil migration [24] and since IL-8 is a neutrophil pro-survival
mediator [54], we wanted to assess if the angiopoietins and IL-
8 could cooperate on neutrophil viability. First, we addressed the0
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Fig. 5. BN 52021, a PAF receptor antagonist, did not reduce Ang1-mediated pro-
survival effect on neutrophils. Neutrophils were pretreated with or without BN
52021 (50 or 100 μM) or with DMSO (2 μl; concentration used to dissolve BN 52021)
for 1 h. Then, neutrophils were incubated with or without PAF (100 nM) and/or Ang1
(10 nM) for 24 h at 37 °C. *pb0.05; **pb0.01; ***pb0.001 as compared to PBS-
treated cells; ††pb0.01 as compared to PAF-treated cells (100 nM).capacity of IL-8 to promote neutrophil viability. Upon a 24-hour incu-
bation period, we observed a bell-shape concentration-dependent
anti-apoptotic effect of IL-8 (5–200 nM) on neutrophil viability with
an optimal effect being achieved at 25 nM, providing a 34% increase
of neutrophil viability (raising the basal viability from 43.4 to 58.0%)
(Suppl. data Fig. 2). Neutrophils were then treated with Ang1
(0.1–10 nM) in the presence or absence of IL-8 (25 nM) for 24 h.
The combination of IL-8 (25 nM) with Ang1 (10 nM) provided an ad-
ditive effect, increasing basal neutrophil viability by 56%. This combi-
nation provided also a signiﬁcant increase of neutrophil viability as
compared to cells treated with Ang1 (10 nM) alone (Fig. 6). Neutro-
phils were also treated with Ang1 (0.1 nM) to assess whether IL-
8 (25 nM) could prime an effect of Ang1 at a concentration, which
by itself, does not provide a signiﬁcant effect on neutrophil viability
(Fig. 6). In addition, IL-8 or Ang1-treated neutrophils had a signiﬁcant
decrease of cell apoptosis, which was also signiﬁcant upon the combi-
nation of IL-8 (25 nM) and Ang1 (10 nM) (Fig. 6). Finally, treatment
of the neutrophils with IL-8 (25 nM) and Ang1 (10 nM), alone or
combined, led to a signiﬁcant decrease of cell necrosis (Fig. 6).
3.6. Contribution of IL-8 on Ang1 pro-survival activity
Both angiopoietins are known to promote similar pro-inﬂammatory
activities in neutrophils [22,24]. However, in our current set of experi-
ments, we demonstrate differential activities of Ang1 and Ang2 on neu-
trophil viability. In addition, we recently observed that Ang1, but not
Ang2, induces IL-8 synthesis and release from neutrophils in a
concentration-dependent manner with an optimal effect at 10 nM and
within 2 h post-stimulation [77]. Therefore, we wanted to address
whether IL-8was implicated in Ang1-induced neutrophil viability. Neu-
trophils were pretreated with goat anti-human IL-8 blocking IgG anti-
bodies (20–100 μg/ml) or control goat IgG isotype (100 μg/ml) for 2 h
before stimulation with PBS, IL-8 (25 nM) or Ang1 (10 nM) for an addi-
tional 22 h. Treatment with control goat IgG or with anti-IL-8 blocking
antibodies (100 μg/ml) had no effect on basal neutrophil viability
(Fig. 7). Pretreatment with anti-IL-8 blocking antibodies reduced both
IL-8 (25 nM) and Ang1 (10 nM)-induced neutrophil viability in a
concentration-dependent manner with a maximal effect at 100 μg/ml
for IL-8 (92% decrease) and 50 μg/ml for Ang1 (81% decrease) (Fig. 7).
In addition, treatment with IL-8 signiﬁcantly decreased both apoptotic
and necrotic neutrophils, whereas pretreatmentwith anti-IL-8 blocking
antibodies (100 μg/ml) provided a trend to reverse the effect of IL-8 on
neutrophil apoptosis, and signiﬁcantly reversed the effect of IL-8 on
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antibodies (20–100 μg/ml) for 2 h. Then, neutrophils were incubated with or without
IL-8 (25 nM) or Ang1 (10 nM) for 22 h at 37 °C. *pb0.05; **pb0.01; ***pb0.001 as
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363E. Dumas et al. / Biochimica et Biophysica Acta 1823 (2012) 358–367neutrophil necrosis. Similarly, Ang1 also decreased signiﬁcantly neutro-
phil apoptosis and necrosis, whereas pretreatmentwith anti-IL-8 block-
ing antibodies (50 and 100 μg/ml) signiﬁcantly reversed only the effect
of Ang1 on neutrophil necrosiswhile having a trend to reverse the effect
of Ang1 on neutrophil apoptosis (Fig. 7).cr
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183.7. Contribution of IL-8 on PAF pro-survival activity
Since Ang1 and PAF are both capable to promote IL-8 synthesis
and release by the neutrophils [77], and that Ang1 pro-survival activ-
ity is IL-8-dependent, we thus wanted to address if PAF pro-survival
activity is also IL-8-dependent. Neutrophils were pretreated with
goat anti-human IL-8 blocking IgG antibodies (20–100 μg/ml) or con-
trol goat IgG isotype (100 μg/ml) for 2 h before stimulation with PBS
or PAF (100 nM) for an additional 22 h. Treatment with control goat
IgG or with anti-IL-8 blocking antibodies (100 μg/ml) had no effect
on basal neutrophil viability (Fig. 8). Pretreatment with anti-IL-anti-IL8 (µg/ml)
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Fig. 8. Blocking anti-IL-8 antibodies reduce PAF-mediated pro-survival effect on neu-
trophils. Neutrophils were pretreated with or without blocking anti-human IL-8 IgG
antibodies (20–100 μg/ml) for 2 h. Then, neutrophils were incubated with or without
PAF (100 nM) for 22 h at 37 °C. *pb0.05 and ***pb0.001 as compared to PBS-treated
cells; ◊pb0.05; ◊◊pb0.01; ◊◊◊pb0.001 as compared to PAF-treated cells.8 blocking antibodies (20, 50 and 100 μg/ml) reduced signiﬁcantly
PAF-induced neutrophil viability in a concentration-dependent man-
ner with a maximal effect at 100 μg/ml (92% decrease) (Fig. 8). In ad-
dition, treatment with PAF signiﬁcantly decreased both apoptotic and
necrotic neutrophils, whereas pretreatment with anti-IL-8 blocking
antibodies (20, 50 and 100 μg/ml) provided a trend to reverse the ef-
fect of PAF on neutrophil apoptosis, and signiﬁcantly reversed the ef-
fect of PAF on neutrophil necrosis (Fig. 8).3.8. Neutrophil chemotactic activity
We previously reported the capacity of Ang1 and IL-8 to promote
neutrophil migration [24]. Herein, wewanted to ascertain if the neutro-
phils upon a 24-hour incubation period either under PBS or Ang1 treat-
mentwere still capable tomigrate upon stimulation bypro-chemotactic
mediators such as IL-8 and fMLP. On freshly isolated neutrophils, IL-
8 (25 nM) [24] increased by 6.3-fold the migration of neutrophils
upon a 60-minute incubation period. Similarly, a treatment with fMLP
(0.1–10 μM) [78,79] provided a bell-shaped increase of neutrophil
migration with a peak mediated at 1 μM (13.9-fold) (Fig. 9). Upon a
24-hour incubation period in control media containing either control
vehicle (PBS) or Ang1 (10 nM),we performed a 60-minute chemotactic
assay and observed that the neutrophils maintained a similar capacity
to respond to IL-8 (7.8- and 6.5-fold of increase respectively) and
fMLP (1 μM; 9.3- and 8.1-fold of increase respectively) (Fig. 9).4. Discussion
In the present study, we report for the ﬁrst time that upon Tie2 acti-
vation, Ang1 has a pro-survival activity on neutrophils, whereas Ang2
has no effect. The combination of known pro-inﬂammatory and pro-
survival mediators for the neutrophils, namely PAF and IL-8, provided
an additive effect on Ang1-mediated pro-survival activity. In addition,
using a selective PAF receptor antagonist and blocking IL-8 antibodies,
we delineated that Ang1 pro-survival activity is IL-8 dependent.PBS
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In vitro chemotactic assays were performed in Transwell-96well permeable supports. The
upper and lower parts of the wells were separated by a porous polycarbonate membrane
ﬁlter (3 μmpore size). Brieﬂy, the bottomwellswere loadedwith RPMI containing PBS, IL-
8 (25 nM) or fMLP (0.1–10 μM). The upper wells were loaded with RPMI containing neu-
trophils. In function of the experiments, neutrophils were freshly added post-isolation
(left panel) or pretreated for 24 h with PBS or Ang1 (10 nM) (middle and right panels re-
spectively) prior to a 1-h chemotactic assay. At the end of the incubation period, the
supernatant from the bottom wells was collected, and a count of migrating neutrophils
was assessed with an Amnis ImageStream system. *pb0.05; **pb0.01 as compared to
corresponding PBS-treated cells.
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Ang1 and Ang2 have been reported to promote differential activi-
ties; Ang1 being recognized as a Tie2 receptor agonist, supporting the
maturation and the stabilization of the neovessels, while Ang2 was
recognized as an antagonist, promoting vascular permeability and
the regression of pre-existing vasculature [3,4,14,15]. However,
under speciﬁc conditions, Ang2 can also act as a Tie2 agonist by sup-
porting Tie2 phosphorylation and associated downstream biological
activities [16–19]. For instance, in ECs, Ang1 is recognized to inhibit
apoptosis through the activation of PI3K/Akt and ERK1/2 pathways,
which cooperate to prevent pro-apoptotic caspase-3, -7, and -9 acti-
vation [10,11]. For Ang2, the data are less clear; some groups reported
that Ang2 has pro-apoptotic activities [55,56], whereas others
reported that Ang2 could promote EC survival through the activation
of ERK1/2 and PI3K pathways [17,57]. In addition, we reported that
both angiopoietins share common agonistic pro-inﬂammatory activi-
ties, namely, on their capacity to promote endothelial PAF synthesis
and P-selectin translocation [20–22]. In neutrophils, we reported
the expression of Tie2 receptor, and the capacity of both angiopoie-
tins to induce PAF synthesis, CD11/CD18 (β2-integrin) activation,
neutrophil adhesion and migration [22,24]. This latter effect was
also conﬁrmed by an independent group [65]. In addition, considering
that both angiopoietins can modulate EC viability and induce the syn-
thesis and release of a neutrophil pro-survival mediator, namely PAF
[10,11,17,22,42,55–57], we were led to address the capacity of both
angiopoietins to modulate neutrophil viability, and if so, deﬁne the
role of PAF in that process.
In the current study, we performed a concentration- and time-
dependent assay, and observed that Ang1 is providing a pro-survival ac-
tivity on the neutrophils by delaying the entry of cells into apoptotic and
necrotic phases, while Ang2 had no signiﬁcant effect on basal viability.
In addition, we observed that Ang1/Tie2 interaction is needed to sup-
port Ang1 pro-survival activity, as a pretreatment with selective block-
ing anti-human Tie2 antibodies, almost completely abrogated (≈85%)
Ang1 pro-survival activity in neutrophils. The residual effect could be
due to an incomplete blockade of Tie2 receptor by the selective anti-
bodies, thus, allowing partial Ang1/Tie2 interaction and biological activ-
ity. Another possibility could be that Ang1 can induce some biological
activities upon its binding to speciﬁc integrins, independently from
Tie2 participation [9,80,81]. If so, then it appears that Ang1/integrin in-
teraction would have a minor contribution on Ang1 pro-survival
activity.
4.2. Cooperation and contribution of PAF and IL-8 on Ang1-mediated
pro-survival activity
In addition to the differential capacity of Ang1 to prolong the via-
bility of the neutrophils, as opposed to Ang2, we recently observed
another differential effect between Ang1 and Ang2 on neutrophils. In-
deed, we reported that Ang1 (but not Ang2) promotes IL-8 synthesis
and release from neutrophils [77]. Since IL-8 is a pro-survival media-
tor for the neutrophils [54], we hypothesized that the synthesis and/
or the release of IL-8, might as well, like endogenous PAF supports the
pro-survival activity of Ang1 on neutrophils. Our data demonstrate
that a combination of PAF or IL-8 with Ang1 produced an additive ef-
fect on neutrophil viability. These results are in agreement with pre-
vious studies demonstrating that under in vivo pro-inﬂammatory
environments, different mediators can cooperate to increase neutro-
phil viability, thereby delaying their entry into apoptotic phase,
even up to several days [26] and thus, resulting in an enhanced in-
ﬂammatory state which can become pathological [29].
To delineate the contribution of PAF on Ang1 pro-survival activity
in neutrophils, we addressed the effect of a selective PAF receptor an-
tagonist (BN 52021) [67,68] on Ang1 anti-apoptotic activity. Treat-
ment with BN 52021 did not modulate basal neutrophil viability,whereas it was efﬁcient to prevent pro-survival activity mediated
by exogenous PAF. In addition, in pretreatment, BN 52021 did not in-
hibit Ang1 pro-survival activity on neutrophils, thus, suggesting that
Ang1 anti-apoptotic activity is PAF-independent. We previously
reported that Ang1 and Ang2 could induce PAF synthesis from ECs
through the activation of sPLA2-V, and independently from cPLA2 par-
ticipation [21]. We also observed that both angiopoietins could pro-
mote neutrophil PAF synthesis [22]. In neutrophils, both cPLA2 and
sPLA2-V are expressed and can contribute to PAF synthesis in function
of the stimuli [69,71–73]. Thereby, we addressed the effect of selec-
tive inhibitors of the secreted and cytosolic form of PLA2 on Ang1-
mediated pro-survival activity on neutrophils. Pretreatment of neu-
trophils either with the cPLA2 inhibitor [74–76], AACOCF3, or the
sPLA2 inhibitor [74,75,82], scalaradial, did not reduce Ang1 pro-
survival activity on neutrophils. Consequently, if both angiopoietins
(Ang1 and Ang2) can support the endogenous PAF synthesis from
neutrophils [22], the concentration of PAF synthesized is not sufﬁ-
cient to participate to Ang1-mediated pro-survival activity on the
neutrophils.
Since PAF cannot be considered as the pro-inﬂammatory mediator
supporting Ang1-mediated pro-survival activity, we thus addressed
whether IL-8 release was implicated in Ang1-induced neutrophil via-
bility. Under basal condition, there is no or marginal release of IL-8 by
the neutrophils, and a treatment with an anti-human IL-8 blocking
antibodies did not modulate the basal survival rate. However, in pre-
treatment to Ang1-stimulation, the anti-IL-8 blocking antibodies pro-
vided a marked reduction (≈80%) of Ang1 pro-survival effect.
Consequently, these data are supporting our hypothesis that the syn-
thesis and release of IL-8 plays a pivotal role as a discriminating factor
for the differential capacity of Ang1, as opposed to Ang2, to support
neutrophil viability. The incomplete reduction of Ang1-mediated
pro-survival activity following a pretreatment with IL-8 blocking an-
tibodies could suggest that Ang1 can activate downstream signaling
pathways capable to provide pro-survival/anti-apoptotic activities,
and/or that Ang1 is capable to promote the release of other pro-
survival mediators.
We also reported that PAF is capable to promote IL-8 synthesis
and release by the neutrophils [77]. Since a treatment with exogenous
PAF is capable to promote neutrophil viability, we addressed the con-
tribution of IL-8 on PAF pro-survival activity. By pretreating the neu-
trophils with anti-IL-8 blocking antibodies, we observed an
obliteration of PAF anti-apoptotic activity. These latter observations
demonstrate that the synthesis and release of IL-8 upon a stimulation
of neutrophils either with exogenous Ang1 or PAF is the common fac-
tor responsible for their pro-survival activity.
It is well deﬁned that transvascular migrated neutrophils are play-
ing a major role in the development of pathological inﬂammation by
prolonging their survival half-life, thus, extending their capacity to
promote the synthesis and release of pro-inﬂammatory mediators,
cytokines and metalloproteinases [28,29,83–85]. We and other
groups reported the chemotactic activity of Ang1 and other cytokines
on freshly isolated neutrophils [24,65,86]. Herein, we observed that a
treatment of the neutrophils with Ang1 under acute or prolong time
period did not alter the capacity of the neutrophils to migrate upon
their stimulation by chemotactic mediators, such as fMLP and IL-8.
Previous studies reported that under in vitro conditions, Ang1 pos-
sesses anti-inﬂammatory properties. Ang1 reduces VEGF-induced
leukocyte adhesion onto HUVEC and E-selectin expression [87] and
thrombin-mediated neutrophil adhesion onto EC [88]. Other studies
reported that under in vivo conditions, Ang1 has an anti-
inﬂammatory role as observed in acute lung injury, endotoxic shock
and cardiac remodeling [12,13,89]. Similarly, the genetic overexpres-
sion or overexpression following infection with adenovirus carrying
the Ang1 gene did protect the vasculature from VEGF and irritant-
induced leakage in mice [4,90]. On the other hand, we and other
groups reported that under in vitro conditions Ang1 can have pro-
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been reported that the administration of Ang1 did not inhibit VEGF-
induced vascular permeability but delayed edema resolution, thus
suggesting that Ang1 is not a universal inhibitor of EC permeability
as previously thought [18]. Together, these observations could sug-
gest that Ang1 may have differential biological activities in function
of the biological conditions and environment.
In summary, our study is the ﬁrst one to report that Ang1, upon its
binding to Tie2 receptor, is providing a pro-survival activity on neu-
trophils, as opposed to Ang2, which has no effect. In addition, Ang1
pro-survival activity is mainly driven by its capacity to promote the
synthesis and release of IL-8 by the neutrophils. However, additional
studies will be needed to delineate which intracellular signaling path-
ways are participating in the induction of Ang1 pro-survival and anti-
apoptotic activities on neutrophils. Together, our data provides novel
insight in the capacity of Ang1 to prolong neutrophil viability and to
promote the release of pro-inﬂammatory mediators, which could
contribute to support the development of pathological vascular dis-
eases associated to inﬂammatory response.
Supplementary data to this article can be found online at doi:10.
1016/j.bbamcr.2011.12.002.
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